# NEOTORCH (NCT04158440)

> Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04158440
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Conditions: Stage II-III Non-small Cell Lung Cancer
- Interventions: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab; 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )
- Enrollment: 501
- Primary outcome: MPR rate in stage III population evaluated by BIPR
- Primary outcome: EFS in stage III population evaluated by investigators
- Primary outcome: MPR rate in stage II-III population evaluated by BIPR
- Primary outcome: EFS in stage II-III population evaluated by investigators

## Indexed commentary on NEOTORCH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 73
- Podcasts: 21
- YouTube: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neotorch-nct04158440

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04158440", "email": "<work email>"}; the inbox owner confirms by the emailed link.